Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 7:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1441–1464 of 5,456 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Solid Tumor Malignancies, Cancer Clear all
Completed Phase 1 Interventional

Phase I, Pharmacokinetic, Pharmacodynamic Trial of PTK787 and Paclitaxel in Combination for Advanced Solid Tumors

NCT00731861
View directory record Official record
Conditions
Neoplasm Metastasis, Carcinoma
Interventions
Paclitaxel plus PTK787
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 11, 2014 · Synced Oct 25, 2026, 7:38 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC

NCT04995523
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma
Interventions
AZD2936
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
3
States / cities
Chicago, Illinois • Rochester, Minnesota • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 25, 2026, 7:38 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Yoga Program for Improving the Quality of Life in Couples Coping With Cancer

NCT04607590
View directory record Official record
Conditions
Esophageal Carcinoma, Lung Carcinoma, Malignant Head and Neck Neoplasm, Malignant Solid Neoplasm
Interventions
Best Practice, Quality-of-Life Assessment, Questionnaire Administration, Yoga
Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 25, 2026, 7:38 AM EDT
Recruiting Phase 1 Interventional

Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors

NCT04064359
View directory record Official record
Conditions
Solid Tumor
Interventions
OBT076, a CD205-directed antibody-drug conjugate
Drug
Lead sponsor
Oxford BioTherapeutics Ltd
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
10
States / cities
Phoenix, Arizona • Los Angeles, California • Santa Monica, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 25, 2026, 7:38 AM EDT
Completed Phase 1 Interventional

A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors

NCT02596503
View directory record Official record
Conditions
Relapsed Solid Tumors, Refractory Solid Tumors
Interventions
Eribulin, Irinotecan, Cefixime
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
13 Years to 30 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
3
States / cities
Aurora, Colorado • Lexington, Kentucky • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Oct 25, 2026, 7:38 AM EDT
Completed Phase 1 Interventional

Combination Chemotherapy in Treating Patients With Advanced Cancer

NCT00021073
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
alvocidib, leucovorin calcium, fluorouracil, irinotecan hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 11, 2013 · Synced Oct 25, 2026, 7:38 AM EDT
Completed Phase 2 Interventional

Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors

NCT04609566
View directory record Official record
Conditions
Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
Interventions
brentuximab vedotin, pembrolizumab
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
90
States / cities
Tucson, Arizona • Fayetteville, Arkansas • Rogers, Arkansas + 57 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 25, 2026, 7:38 AM EDT
Completed Phase 1 Interventional

Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL in Subjects With Advanced Solid Tumors

NCT01673438
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
aldoxorubicin
Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Oct 25, 2026, 7:38 AM EDT
Terminated Phase 1 Interventional Results available

INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.

NCT03272464
View directory record Official record
Conditions
Melanoma
Interventions
Trametinib, Dabrafenib, INCB039110
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 22, 2023 · Synced Oct 25, 2026, 7:38 AM EDT
Not listed Phase 1 Interventional

Study of the Farnesyl Transferase Inhibitor, R115777, in Combination With Topotecan (NYU 99-32)

NCT00006199
View directory record Official record
Conditions
Cancer
Interventions
R115777 (farnesyl transferase inhibitor), Topotecan
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 25, 2026, 7:38 AM EDT
Completed Phase 1 Interventional

Chemotherapy in Treating Patients With Advanced Solid Tumors

NCT00003709
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
carbendazim
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
2
States / cities
Fort Sam Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2012 · Synced Oct 25, 2026, 7:38 AM EDT
Completed Phase 1 Interventional Results available

Phase 1 Study Of Aurora Kinase Inhibitor PF-03814735 In Patients With Advanced Solid Tumors

NCT00424632
View directory record Official record
Conditions
Solid Tumors
Interventions
PF-03814735
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 25, 2012 · Synced Oct 25, 2026, 7:38 AM EDT
Terminated Phase 1 Interventional

Safety/Tolerance Study of PPI-2458 in Subjects With Non-Hodgkin's Lymphoma and Solid Tumors

NCT00100347
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma,, Solid Tumors
Interventions
PPI-2458
Drug
Lead sponsor
PRAECIS Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
8
States / cities
Baltimore, Maryland • Boston, Massachusetts • Albuquerque, New Mexico + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2007 · Synced Oct 25, 2026, 7:38 AM EDT
Completed Not applicable Interventional Results available

Hypofractionated Stereotactic Radiosurgery in Treating Patients With Large Brain Metastasis

NCT01705548
View directory record Official record
Conditions
Metastatic Malignant Neoplasm to Brain, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Hypofractionated Radiosurgery
Radiation
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 25, 2026, 7:38 AM EDT
Completed Phase 3 Interventional

Amifostine in Treating Peripheral Neuropathy in Patients Who Have Received Chemotherapy for Cancer

NCT00058071
View directory record Official record
Conditions
Gestational Trophoblastic Tumor, Neurotoxicity, Peripheral Neuropathy, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
amifostine trihydrate
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
57
States / cities
Burbank, California • La Jolla, California • Los Angeles, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2013 · Synced Oct 25, 2026, 7:38 AM EDT
Completed Phase 1 Interventional

Bevacizumab in Treating Young Patients With Refractory Solid Tumors

NCT00085111
View directory record Official record
Conditions
Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
bevacizumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Oct 25, 2026, 7:38 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors

NCT00521144
View directory record Official record
Conditions
Recurrent Small Cell Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
obatoclax mesylate, topotecan hydrochloride, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Oct 25, 2026, 7:38 AM EDT
Terminated Phase 2 Interventional

Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors

NCT02016534
View directory record Official record
Conditions
Stomach Neoplasms
Interventions
AMG 337
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
7
States / cities
New Haven, Connecticut • New York, New York • Rochester, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 25, 2026, 7:38 AM EDT
Recruiting Early Phase 1 Interventional

Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors

NCT07628634
View directory record Official record
Conditions
Adenocarcinoma, Basal Cell Carcinoma, Squamous Cell Carcinoma, Transitional Cell Carcinoma, Ductal Carcinoma, Osteosarcoma, Soft Tissue Sarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Leiomyosarcoma, Melanoma, Germ Cell Tumor, Lymphoma, Endocrine Tumor, Glioma
Interventions
Methionine-Reduced Diet
Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 25, 2026, 7:38 AM EDT
Completed Phase 2 Interventional

Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy

NCT03616834
View directory record Official record
Conditions
Solid Tumors
Interventions
Tomivosertib (eFT-508)
Drug
Lead sponsor
Effector Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
19
States / cities
Tucson, Arizona • Long Beach, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Oct 25, 2026, 7:38 AM EDT
Terminated Phase 2 Interventional Results available

Milademetan in Advanced/Metastatic Solid Tumors

NCT05012397
View directory record Official record
Conditions
Solid Tumors, Head and Neck Carcinoma, Cholangiocarcinoma, Sarcoma, Lung Adenocarcinoma, Bladder Urothelial Carcinoma, Stomach Adenocarcinoma, Breast Cancer Invasive, Ovarian Carcinoma, Cervical Cancer, Non Small Cell Lung Cancer, Gastric Cancer, Biliary Tract Cancer, Melanoma, Pancreas Cancer, MDM2 Gene Amplification, Testicular Germ Cell Tumor, Adrenocortical Carcinoma
Interventions
RAIN-32
Drug
Lead sponsor
Rain Oncology Inc
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
14
States / cities
Palo Alto, California • Fort Myers, Florida • St. Petersburg, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Oct 25, 2026, 7:38 AM EDT
Completed Phase 1 Interventional

A Study of ABT-414 in Subjects With Solid Tumors

NCT01741727
View directory record Official record
Conditions
Squamous Cell Tumors
Interventions
ABT-414
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 99 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
5
States / cities
Scottsdale, Arizona • Chicago, Illinois • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Oct 25, 2026, 7:38 AM EDT
Recruiting Phase 1Phase 2 Interventional

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

NCT05431270
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
Interventions
Mavrostobart (PT199), Tislelizumab, Gemcitabine + nab-Paclitaxel, Docetaxel, Pemetrexed, Gemcitabine, Carboplatin + Pemetrexed, Pembrolizumab + Carboplatin + Pemetrexed
Drug
Lead sponsor
Phanes Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
6
States / cities
Huntersville, North Carolina • Oklahoma City, Oklahoma • Nashville, Tennessee + 3 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 25, 2026, 7:38 AM EDT
Completed Phase 1 Interventional

PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma

NCT00004002
View directory record Official record
Conditions
Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
bortezomib
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
5
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 9, 2012 · Synced Oct 25, 2026, 7:38 AM EDT